{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-010594","form_type":"8-K","ticker":"VYCO","cik":"0001424768","company_name":"VYCOR MEDICAL INC","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.256231+00:00","generated_at":"2026-05-21T04:47:19.698292+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vycor Medical Q1 revenue up 30% to $436k; operating profit turns positive","bullets":["Revenue of $436,378 (+30% YoY); Vycor Medical division revenue $418,520 (+31%).","Non-GAAP cash operating profit of $21,619 vs $8,452 in prior year.","Gross margin 82% (down from 89%) due to validation, shipping costs and sales mix.","New distribution agreements signed for France and Spain; three VBAS clinical papers published.","NovaVision division revenue $17,858 (-3% YoY), remains in development stage."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-010594","json":"https://secwatch.observer/filing/0001641172-25-010594.json","markdown":"https://secwatch.observer/filing/0001641172-25-010594.md","text":"https://secwatch.observer/filing/0001641172-25-010594.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1424768/000164117225010594/0001641172-25-010594-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1424768/000164117225010594/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:47:19.698292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}